| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Revolution Health and Wellness |
| URL | revolutionhealth.org/blogs/news/lower-hematocrit-testosterone-therapy-without-phlebotomy (opens in a new tab) |
Specific Claim Evaluated
Testosterone-related erythrocytosis is usually preventable by changing formulation or dose, and phlebotomy is indicated for hematocrit of 54% to 55% or higher.
Primary Research Supporting or Contradicting the Claim
The Endocrine Society guideline recommends monitoring hematocrit and, if it exceeds 54%, stopping therapy until it falls to a safe level, then evaluating for hypoxia and sleep apnea and reinitiating at a reduced dose (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
Injectable formulations raise hematocrit more than transdermal ones, and dose or formulation changes are reasonable. When hematocrit exceeds 54%, guidelines advise withholding testosterone, not continuing treatment with phlebotomy.
Rationale for Grade
The page's mechanisms and formulation ranking are consistent with the literature, but it presents uncited quantitative estimates and omits the guideline recommendation to withhold therapy above 54%, framing phlebotomy as the main threshold-based response.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs"